Eylea Global Market 2024 – By Growth, Drivers, Growth Trends, Analysis Forecast To 2033 | Regeneron Pharmaceuticals Inc., Bayer AG, Santen Pharmaceutical Co Ltd

The Eylea  by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Eylea Market:
https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

According to The Business Research Company’s Eylea, The eylea market size has grown strongly in recent years. It will grow from $7.8 billion in 2023 to $8.19 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%.  The growth in the historic period can be attributed to diabetic macular edema (dme) prevalence, clinical efficacy and safety profile, competition with other anti-vegf therapies, approval for various retinal conditions, shift towards intravitreal injections.

The eylea market size is expected to see strong growth in the next few years. It will grow to $10.16 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%.  The growth in the forecast period can be attributed to emerging therapeutic indications, introduction of biosimilar competition, increasing awareness and diagnosis, real-world evidence and post-market studies, patient preference for less frequent injections. Major trends in the forecast period include advancements in imaging technologies, telemedicine and remote monitoring, patient assistance programs, advances in drug delivery technologies, retinal imaging technologies, clinical trials for new indications.

The increasing prevalence of ocular diseases is expected to propel the Eylea market. Ocular diseases refer to an eye condition that interferes with the ability of the eye properly function and negatively affects the vision and clarity of the eye. They often don’t have any symptoms until they have become very advanced. Eylea treats conditions such as ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, which damages the retina or macula that affects the vision. Eylea blocks the protein that develops new weaker blood vessels and slows down the retina’s swelling caused by a blockage in the blood vessels. For instance, in October 2022, according to the BrightFocus Foundation, a US-based nonprofit organization dedicated to advancing research and support for macular degeneration and glaucoma, there were currently 80 million individuals with glaucoma across the globe, with a projected increase to more than 111 million by the year 2040.  Therefore, the increasing prevalence of ocular diseases is driving the Eylea market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

The eylea market covered in this report is segmented –
1) By Product: Prefilled Syringe Package, Vial Package
2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders
3) By Application: Hospitals, Retail Pharmacy, Other Applications

Research and developments are a key trend gaining popularity in the eylea market. Developing cutting-edge technical solutions is a top priority for the major industry players in eylea. For instance, in August 2023, Regeneron Pharmaceuticals, Inc., a US-based global biotechnology company developing medicine for serious diseases, received US FDA approval for Eylea HD (aflibercept) injection 8 mg to address patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The administration schedule involves an initial period of every four weeks for the first three months across all indications, followed by adjusted intervals of every eight to 16 weeks for wAMD and DME, and every eight to 12 weeks for diabetic retinopathy.

The eylea market report table of contents includes:
1. Executive Summary
2. Eylea Market Characteristics
3. Eylea Market Trends And Strategies
4. Eylea Market – Macro Economic Scenario
5. Global Eylea Market Size and Growth
……………..
31. Global Eylea Market Competitive Benchmarking
32. Global Eylea Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Eylea Market
34. Eylea Market Future Outlook and Potential Analysis
35. Appendix

Read Related Topics:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model